The Global Assisted Reproductive Technology (ART) market is expected to be a lucrative market due to increasing obesity, rising disposable incomes, growing number of infertility issues, government support for infertility procedures, increasing number of smokers, stress, and pollution.
According to the International Council on Information Dissemination, one in every six couples is suffering from infertility issues. With the growing infertility issues, the ART industry has grown 10% every year. Moreover, the WHO 2014 report states that out of every 1.9 billion obese people, 600 million people are overweight.
Request to Sample of This Report @ http://www.grandviewresearch.com/industry-analysis/assisted-reproductive-technology-market
The ART market is segmented on the basis of procedures and ART cycles. In vitro fertilization dominated the procedure segment of the market owing to its higher success rates, favorable reimbursement policies, and technology updates. To avoid multiple births caused due to multiple sperm injection, time-lapse imaging has been introduced. With this technology, egg division can be monitored and fate of the embryo can be decided prior.
Frozen donor dominates the ART market as compared to fresh donor. With technological shifts, many companies have now started online ordering, a strategy to expand and cover more market shares.
North America dominates the industry due to awareness in people towards various reproductive technologies and government initiatives to undertake extensive research. To address various fertility issues, the Centers for Disease Control and Prevention (CDC) developed National Action Plan.
In Europe, an expert group is appointed to address various demographic issues. In addition, acceptance of the three-parent IVF procedure is expected to boom the ART industry in Europe.
Rising disposable incomes due to gain in education, low fertility rate, and family planning technology are some of the drivers attributing to the market expansion. The Asia Pacific Initiative on Reproduction (ASPIRE) strives to improve the quality of patient care by assisting physicians and clinicians to guide patients with various available reproductive technologies.
Cryolab Ltd., Origio, Parallabs, IrvineScientific, European Sperm Bank, Cosmos Biomedical, and Microm UK Ltd. dominate the industry. EmbryoScope by Parallabs was launched in May 2013. This time-lapse monitoring was used in November 2014 for research by the American Society of Reproductive Medicine, where they increased the implantation and pregnancy rates.
In September 2012, Integramed America Inc. was acquired by Sagard Capital Partners LP. The acquisition aims to expand Sagard Capital Partners LP presence in new areas with the help of Integramed America Inc.
Industry players are continuously trying to introduce new ways to provide improved patient care and at the same time achieve more revenue share and leadership. Key player initiatives along with government funding are expected to make the ART more lucrative.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
For More Information, Visit Grand View Research
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
Toll Free: 1-888-202-9519
Blog Site: http://www.grandviewresearchinc.blogspot.in/